Lignocaine Nebulization for Pharyngitis
Lignocaine nebulization is not appropriate for routine treatment of uncomplicated pharyngitis and should not be used at all for this indication. Standard pharyngitis management relies on appropriate antibiotics when indicated (penicillin or amoxicillin for confirmed Group A streptococcal infection) combined with systemic analgesics (NSAIDs or acetaminophen), which provide adequate symptom relief without the risks and complexity of nebulized local anesthetics 1, 2.
Why Nebulized Lignocaine Is Not Indicated
No guideline support exists for nebulized lignocaine in pharyngitis treatment—current evidence-based guidelines from the Infectious Diseases Society of America, American College of Physicians, and American Academy of Family Physicians make no mention of this intervention for sore throat management 1, 2.
Nebulized lignocaine is reserved for airway topicalization during medical procedures such as awake intubation or bronchoscopy, not for symptomatic pharyngitis treatment 3, 4.
Absorption variability and safety concerns make nebulization problematic—systemic absorption from nebulized lignocaine is unpredictable, and the intervention carries risks of local anesthetic toxicity including CNS effects (dizziness, tinnitus, seizures) and cardiac effects (arrhythmias, myocardial depression) at plasma concentrations that can occur with topical administration 3.
Appropriate First-Line Management
For Confirmed Group A Streptococcal Pharyngitis
Penicillin or amoxicillin for 10 days is the treatment of choice, providing narrow-spectrum coverage, proven efficacy in preventing acute rheumatic fever, low adverse effects, and modest cost 1, 2.
NSAIDs (ibuprofen) are the preferred analgesic for moderate to severe symptoms or high fever, as they are more effective than acetaminophen for fever and pain control 1, 2.
Acetaminophen is an effective alternative when NSAIDs are contraindicated 2.
For Viral Pharyngitis
Antibiotics should not be prescribed when viral features are present (cough, rhinorrhea, hoarseness, oral ulcers), as they provide no clinical benefit and promote antimicrobial resistance 1, 2.
Symptomatic treatment with NSAIDs or acetaminophen is the primary management strategy 1, 2.
Alternative Topical Options (If Desired)
Topical anesthetic lozenges containing lidocaine 8 mg have demonstrated efficacy in reducing sore throat pain intensity over 2-48 hours in placebo-controlled trials, with good tolerability and low adverse event rates 5, 6.
Lidocaine throat spray (10% solution, 10 actuations) has shown superiority over nebulized lidocaine in reducing throat symptoms, with better patient satisfaction and lower total drug dose 4.
These topical formulations are safer than nebulization because they deliver controlled doses directly to the pharynx with minimal systemic absorption 5, 6, 4.
Critical Safety Contraindications for Lignocaine
Weight less than 40 kg is an absolute contraindication to lignocaine administration 3.
Cardiac disease, electrolyte disorders, seizure disorders, renal or hepatic insufficiency, pregnancy/lactation, and neurological disorders are all contraindications 3.
Maximum topical dose is 9 mg/kg of lean body weight to avoid systemic toxicity 3.
Common Pitfalls to Avoid
Do not use nebulized lignocaine as a substitute for appropriate antibiotic therapy in confirmed bacterial pharyngitis—this delays effective treatment 1, 2.
Do not assume that more aggressive local anesthetic delivery (nebulization) is superior to simpler, safer options like oral analgesics or topical lozenges/sprays 5, 6, 4.
Avoid aspirin in children with pharyngitis due to Reye syndrome risk 1, 2.
Do not test or treat asymptomatic household contacts of patients with streptococcal pharyngitis 1.